Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
304-03-008 ISMRM Abstract

Extremely elevated total creatine and myo-inositol are indicators of molecular glioblastoma

Primary: Contrast Mechanisms - Spectroscopy
Secondary: Neuro - Tumors
304-03-008 · Precision MRI: Advanced Quantitative Imaging and Biomarkers for Brain Tumors · Monday, 11 May, 1:50 PM–3:40 PM · Ballroom East
Keywords: Glioma classification Creatine Noninvasive diagnosis MR Spectroscopy (MRS) Glioblastomas
Accepted
Francesca Ravera 1,2, Capucine Cadin1, Alberto Picca1,3, Bertrand Mathon1,3, Matteo Bendini4, Stephane Lehericy1,3, Mehdi Touat1,3, Franck Bielle1,3, Marc Sanson1,3, Malgorzata Marjanska5, Lucia Nichelli1,3, Francesca Branzoli1
1Paris Brain Institute - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne University, Paris, France
2Siemens Healthcare SAS, Courbevoie, France
3Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, Paris, France
4Neuroradiology Unit, Local Health Authority n.2 Marca Trevigiana, Treviso, Italy
5Center for Magnetic Resonance Research, Dept. of Radiology, University of Minnesota, Minneapolis, United States of America
Presenting Author: Francesca Ravera

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018–2022. Neuro Oncol. 2025;27(Supplement_4):iv1-iv66. doi:10.1093/neuonc/noaf194 [doi]
2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106 [doi]
3. Guo X, Gu L, Li Y, et al. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors. Front Oncol. 2023;13. doi:10.3389/fonc.2023.1200815 [doi]
4. Agarwal A, Edgar MA, Desai A, Gupta V, Soni N, Bathla G. Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma. American Journal of Neuroradiology. 2024;45(8):1006-1012. doi:10.3174/ajnr.A8225 [doi]
5. Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol. 2018;136(5):805-810. doi:10.1007/s00401-018-1913-0 [doi]
6. Martinez Luque E, Liu Z, Sung D, et al. An Update on MR Spectroscopy in Cancer Management: Advances in Instrumentation, Acquisition, and Analysis. Radiol Imaging Cancer. 2024;6(3). doi:10.1148/rycan.230101 [doi]
7. Branzoli F, Di Stefano AL, Capelle L, et al. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro Oncol. 2018;20(7):907-916. doi:10.1093/neuonc/nox214 [doi]
8. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Sci Transl Med. 2012;4(116). doi:10.1126/scitranslmed.3002693 [doi]
9. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624-629. doi:10.1038/nm.2682 [doi]
10. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneousin vivo spectral editing and water suppression. NMR Biomed. 1998;11(6):266-272. doi:10.1002/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J [doi]
11. Tkák I, Starcuk Z, Choi IY, Gruetter R. In vivo1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med. 1999;41(4):649-656. doi:10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G [doi]
12. Gruetter R, Tkác I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med. 2000;43(2):319-323. doi:10.1002/(SICI)1522-2594(200002)43:2<319::AID-MRM22>3.0.CO;2-1 [doi]
13. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672-679. doi:10.1002/mrm.1910300604 [doi]
14. Bumes E, Wirtz FP, Fellner C, et al. Non-invasive prediction of IDH mutation in patients with glioma WHO II/III/IV based on F-18-FET pet-guided in vivo1H-magnetic resonance spectroscopy and machine learning. Cancers (Basel). 2020;12(11):1-15. doi:10.3390/cancers12113406 [doi]
15. Ozturk-Isik E, Cengiz S, Ozcan A, et al. Identification of IDH and TERTp mutation status using 1H-MRS in 112 hemispheric diffuse gliomas. Journal of Magnetic Resonance Imaging. 2020;51(6):1799-1809. doi:10.1002/jmri.26964 [doi]
16. Bulik M, Jancalek R, Vanicek J, Skoch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg. 2013;115(2):146-153. doi:10.1016/j.clineuro.2012.11.002 [doi]
17. Horská A, Barker PB. Imaging of Brain Tumors: MR Spectroscopy and Metabolic Imaging. Neuroimaging Clin N Am. 2010;20(3):293-310. doi:10.1016/j.nic.2010.04.003 [doi]
18. Weinberg BD, Kuruva M, Shim H, Mullins ME. Clinical Applications of Magnetic Resonance Spectroscopy in Brain Tumors. Radiol Clin North Am. 2021;59(3):349-362. doi:10.1016/j.rcl.2021.01.004 [doi]
19. Durmo F, Rydelius A, Baena SC, et al. Multivoxel 1H-MR Spectroscopy Biometrics for Preoprerative Differentiation between Brain Tumors. Tomography. 2018;4(4):172-181. doi:10.18383/j.tom.2018.00051 [doi]
20. Ligneul C, Palombo M, Hernández-Garzón E, et al. Diffusion-weighted magnetic resonance spectroscopy enables cell-specific monitoring of astrocyte reactivity in vivo. Neuroimage. 2019;191:457-469. doi:10.1016/j.neuroimage.2019.02.046 [doi]
21. Genovese G, Diaz-Fernandez B, Lejeune FX, et al. Longitudinal Monitoring of Microstructural Alterations in Cerebral Ischemia with in Vivo Diffusion-weighted MR Spectroscopy. Radiology. 2023;306(3). doi:10.1148/radiol.220430 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/304-03-008